Clinical Trial to Treat Brain Tumors with Electric Fields

Jun 04, 2010

(PhysOrg.com) -- The University of Illinois at Chicago is taking part in an international, multi-center study for patients newly diagnosed with the most common and aggressive type of brain tumor, glioblastoma multiforme, or GBM.

The clinical trial will evaluate the safety and efficacy of an investigational device that targets rapidly growing with intermediate frequency electrical fields. Treatment with the device will be tested in combination with standard-of-care therapy and compared to standard-of-care therapy alone.

The Novo-TTF is a non-invasive medical device that disrupts the division of cancer cells in the brain using alternating electrical fields called "tumor-treating fields" delivered to the surface of the scalp by insulated electrodes.

Standard treatment includes surgical removal of the tumor, radiation and chemotherapy with an oral drug called temozolomide.

Dr. Herbert Engelhard, associate professor of and site investigator for the trial at UIC, said that in a pilot study, "early data suggest that this investigational treatment may increase the length of time before disease progression and increase median overall survival in newly diagnosed GBM patients."

"The concept is quite simple," he said. "The tumor-treating fields cause the quickly growing cancer cells to die instead of dividing. And because brain have different electrical properties than healthy cells, the healthy cells are spared from damage."

After a baseline MRI is used to determine the location of the tumor, physicians place several electrodes on the patient's shaved head. The electrodes are connected to the Novo-TTF powered by a portable battery. The patient remains on the portable device for 22 hours a day, indefinitely, while continuing his or her daily activities.

Approximately five out of every 100,000 Americans are diagnosed each year with glioblastoma, according to the American Brain Tumor Association. is the most deadly of all brain tumors. Standard therapy often does not provide a cure and causes side effects that diminish quality of life.

"Unfortunately, many patients with these aggressive brain tumors do not have many options," said Engelhard. "The goal is to provide new treatment options, improve survival and hopefully improve their quality of life."

While not considered a cure for the deadly brain tumor, the treatment may extend life for some people, said Engelhard. However, as the research is in its early stages, the benefit of Novo-TTF for patients with GBM has not yet been established.

The trial will enroll approximately 283 patients at 12 U.S. centers and nine centers in Europe. Two-thirds of the patients will receive continuous therapy with the NovoTTF-100A in addition to standard treatment; the other one-third will receive the standard treatment alone. All patients will be evaluated for .

UIC currently has three patients enrolled.

One patient, Gerald Bagnowski of Chicago, said that he continues his active lifestyle, which includes being a part-time elementary school gym teacher and an avid golfer, despite his diagnosis and treatment with the NovoTTF.

"To me, it was a life-or-death situation, and I felt the study was in my best interest," said Bagnowski, who is married and has three adult sons.

In 2006, in an earlier clinical trial for patients who had recurrent glioblastoma, UIC enrolled the first person in the U.S. who was randomly assigned to receive the novel NovoTTF therapy.

Today, 54-year-old Daniel Torres of Chicago has worn the device for 3 1/2 years.

Results of the previous clinical trial for patients with recurrent GBM have not yet been published.

Explore further: US scientists make embryonic stem cells from adult skin

add to favorites email to friend print save as pdf

Related Stories

Clinical trial evaluating brain cancer vaccine is underway

Oct 19, 2007

A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center. The study will evaluate the addition of the vaccine following standard therapy with surgery ...

Recommended for you

Leeches help save woman's ear after pit bull mauling

Apr 18, 2014

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

New pain relief targets discovered

Apr 17, 2014

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching ...

User comments : 0

More news stories

Filipino tests negative for Middle East virus

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

Study says we're over the hill at 24

(Medical Xpress)—It's a hard pill to swallow, but if you're over 24 years of age you've already reached your peak in terms of your cognitive motor performance, according to a new Simon Fraser University study.

NASA's space station Robonaut finally getting legs

Robonaut, the first out-of-this-world humanoid, is finally getting its space legs. For three years, Robonaut has had to manage from the waist up. This new pair of legs means the experimental robot—now stuck ...

Ex-Apple chief plans mobile phone for India

Former Apple chief executive John Sculley, whose marketing skills helped bring the personal computer to desktops worldwide, says he plans to launch a mobile phone in India to exploit its still largely untapped ...

Egypt archaeologists find ancient writer's tomb

Egypt's minister of antiquities says a team of Spanish archaeologists has discovered two tombs in the southern part of the country, one of them belonging to a writer and containing a trove of artifacts including reed pens ...

Airbnb rental site raises $450 mn

Online lodging listings website Airbnb inked a $450 million funding deal with investors led by TPG, a source close to the matter said Friday.